Literature DB >> 12760865

In vitro activities of linezolid combined with other antimicrobial agents against Staphylococci, Enterococci, Pneumococci, and selected gram-negative organisms.

Michael T Sweeney1, Gary E Zurenko.   

Abstract

The activities of linezolid, an oxazolidinone antibacterial agent active against gram-positive organisms, alone and in combination with 35 antimicrobial agents were tested in vitro against methicillin-sensitive (n = 1 to 2 strains) and methicillin-resistant (n = 8 to 10) Staphylococcus aureus strains; vancomycin-sensitive (n = 6) and vancomycin-resistant (n = 6 to 8) Enterococcus faecalis strains; vancomycin-sensitive (n = 5) and vancomycin-resistant (n = 6) Enterococcus faecium strains; penicillin-sensitive (n = 2 to 5), penicillin-intermediate (n = 5 to 6), and penicillin-resistant (n = 5 to 6) Streptococcus pneumoniae strains; Escherichia coli (n = 6); and Klebsiella pneumoniae (n = 6). The fractional inhibitory concentration indices of linezolid in combination with other antimicrobial agents for the organisms tested were generated on checkerboard broth microdilution plates prepared by a semiautomated method. Of 1,380 organism-drug combinations, 1,369 (99.2%) combinations of linezolid with 28 antimicrobial drugs were indifferent, 9 combinations (0.65%) of linezolid with 6 drugs (amoxicillin, erythromycin, imipenem, sparfloxacin, teicoplanin, and tetracycline) were synergistic, and 2 combinations (0.15%) of linezolid with 2 drugs (ofloxacin and sparfloxacin) were antagonistic. Overall, the in vitro data demonstrated that linezolid combined with other antimicrobial agents primarily produces an indifferent response, with infrequent occurrences of synergism and antagonism.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12760865      PMCID: PMC155858          DOI: 10.1128/AAC.47.6.1902-1906.2003

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  20 in total

1.  Comparison of methods for assessing synergic antibiotic interactions.

Authors:  M L Mackay; K Milne; I M Gould
Journal:  Int J Antimicrob Agents       Date:  2000-07       Impact factor: 5.283

Review 2.  Antibiotic combinations: should they be tested?

Authors:  G M Eliopoulos; C T Eliopoulos
Journal:  Clin Microbiol Rev       Date:  1988-04       Impact factor: 26.132

3.  A pharmacokinetic evaluation of concomitant administration of linezolid and aztreonam.

Authors:  T L Sisson; G L Jungbluth; N K Hopkins
Journal:  J Clin Pharmacol       Date:  1999-12       Impact factor: 3.126

4.  Evaluation of Alamar colorimetric MIC method for antimicrobial susceptibility testing of gram-negative bacteria.

Authors:  C N Baker; S N Banerjee; F C Tenover
Journal:  J Clin Microbiol       Date:  1994-05       Impact factor: 5.948

5.  In vitro activities of linezolid against important gram-positive bacterial pathogens including vancomycin-resistant enterococci.

Authors:  G A Noskin; F Siddiqui; V Stosor; D Hacek; L R Peterson
Journal:  Antimicrob Agents Chemother       Date:  1999-08       Impact factor: 5.191

6.  Synergic activity, for anaerobes, of trovafloxacin with clindamycin or metronidazole: chequerboard and time-kill methods.

Authors:  L M Ednie; K L Credito; M Khantipong; M R Jacobs; P C Appelbaum
Journal:  J Antimicrob Chemother       Date:  2000-05       Impact factor: 5.790

Review 7.  Synergy of fluoroquinolones with other antimicrobial agents.

Authors:  H C Neu
Journal:  Rev Infect Dis       Date:  1989 Jul-Aug

8.  In vitro activities of linezolid alone and in combination with amoxicillin, clarithromycin, and metronidazole against Helicobacter pylori.

Authors:  A M Hirschl; P Apfalter; A Makristathis; M L Rotter; M Wimmer
Journal:  Antimicrob Agents Chemother       Date:  2000-07       Impact factor: 5.191

9.  In vitro activities of quinupristin-dalfopristin and cefepime, alone and in combination with various antimicrobials, against multidrug-resistant staphylococci and enterococci in an in vitro pharmacodynamic model.

Authors:  George P Allen; Raymond Cha; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

10.  In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents.

Authors:  G E Zurenko; B H Yagi; R D Schaadt; J W Allison; J O Kilburn; S E Glickman; D K Hutchinson; M R Barbachyn; S J Brickner
Journal:  Antimicrob Agents Chemother       Date:  1996-04       Impact factor: 5.191

View more
  17 in total

1.  In vitro activities of DA-7867, a novel oxazolidinone, against recent clinical isolates of aerobic and anaerobic bacteria.

Authors:  Dongeun Yong; Jong Hwa Yum; Kyungwon Lee; Yunsop Chong; Sung Hak Choi; Jae Keol Rhee
Journal:  Antimicrob Agents Chemother       Date:  2004-01       Impact factor: 5.191

2.  Treatment of meningitis due to methicillin-resistant Staphylococcus epidermidis with linezolid.

Authors:  Wolfgang A Krueger; Bernd Kottler; Bernd E Will; Alexandra Heininger; Heinz Guggenberger; Klaus E Unertl
Journal:  J Clin Microbiol       Date:  2004-02       Impact factor: 5.948

3.  In vitro and in vivo synergistic activities of linezolid combined with subinhibitory concentrations of imipenem against methicillin-resistant Staphylococcus aureus.

Authors:  Cédric Jacqueline; Dominique Navas; Eric Batard; Anne-Françoise Miegeville; Virginie Le Mabecque; Marie-France Kergueris; Denis Bugnon; Gilles Potel; Jocelyne Caillon
Journal:  Antimicrob Agents Chemother       Date:  2005-01       Impact factor: 5.191

4.  Exploring the pharmacodynamic interactions between tedizolid and other orally bioavailable antimicrobials against Staphylococcus aureus and Staphylococcus epidermidis.

Authors:  Brian J Werth
Journal:  J Antimicrob Chemother       Date:  2017-05-01       Impact factor: 5.790

5.  Pharmacodynamic and response surface analysis of linezolid or vancomycin combined with meropenem against Staphylococcus aureus.

Authors:  Sebastian G Wicha; Martin G Kees; Janin Kuss; Charlotte Kloft
Journal:  Pharm Res       Date:  2015-01-30       Impact factor: 4.200

6.  Activity and synergistic interactions of stilbenes and antibiotic combinations against bacteria in vitro.

Authors:  S Nishanth Kumar; J V Siji; Bala Nambisan; C Mohandas
Journal:  World J Microbiol Biotechnol       Date:  2012-07-11       Impact factor: 3.312

7.  Managing Severe Community-Acquired Pneumonia Due to Community Methicillin-Resistant Staphylococcus aureus (MRSA).

Authors:  Jason C Kwong; Kyra Chua; Patrick G P Charles
Journal:  Curr Infect Dis Rep       Date:  2012-06       Impact factor: 3.725

8.  Combination of Tedizolid and Daptomycin against Methicillin-Resistant Staphylococcus aureus in an In Vitro Model of Simulated Endocardial Vegetations.

Authors:  Jordan R Smith; Juwon Yim; Seth Rice; Kyle Stamper; Razie Kebriaei; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2018-04-26       Impact factor: 5.191

9.  Linezolid alone or combined with rifampin against methicillin-resistant Staphylococcus aureus in experimental foreign-body infection.

Authors:  Daniela Baldoni; Manuel Haschke; Zarko Rajacic; Werner Zimmerli; Andrej Trampuz
Journal:  Antimicrob Agents Chemother       Date:  2008-12-15       Impact factor: 5.191

10.  In vitro 24-hour time-kill studies of vancomycin and linezolid in combination versus methicillin-resistant Staphylococcus aureus.

Authors:  Shveta Rani Singh; Alfred E Bacon; David C Young; Kimberly A Couch
Journal:  Antimicrob Agents Chemother       Date:  2009-07-27       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.